IDx Technologies founder and CEO Michael Abramoff is succeeding Gary Seamans as executive chairman as the Coralville-based medical company announced new leadership appointments across its executive leadership team. Other appointments include John Bertrand succeeding Abramoff as CEO; Seth Rainford being appointed president and COO; and Danika Simonson being hired in the newly created chief of staff position. IDx Technologies is the creator of IDx-DR, an FDA-authorized autonomous artificial intelligence system that detects
IDx-DR
June 27, 2019
New CPT code for automated point-of-care retinal imaging
IDx, a Coralville startup that developed the first FDA-authorized artificial intelligence diagnostics system, announced this week that the American Medical Association’s (AMA) Current Procedural Terminology (CPT) Editorial Panel has accepted a new category 1 CPT code for automated point-of-care retinal imaging. This new code, submitted by the American Academy of Ophthalmology (AAO) with the support of IDx, facilitates correct billing of IDx-DR, an FDA-cleared autonomous AI system that detects diabetic
May 30, 2019
Growing IDx
Coralville startup becomes the first FDA-authorized artificial intelligence diagnostics system One of the first FDA-authorized artificial intelligent solutions in ophthalmology sprouted in the laboratories of University of Iowa. The idea for advanced technology to help patients who could be going blind had been planted years earlier – first in the Netherlands, by an ophthalmology medical resident with an interest in computer science, then refined in Japan, where his interests evolved
May 1, 2019
IDx CEO Abramoff receives 2019 Cultivation Corridor Iowa Biotech Leader award
Cultivation Corridor Executive Director Billi Hunt presented the 2019 Cultivation Corridor Iowa Biotech Leader Award to Dr. Michael Abramoff, founder and CEO of IDx Technologies. Abramoff accepted the award on Tuesday during a reception at Partnering for Growth Biotech Innovation Showcase and Forum, an annual conference by the Iowa Biotechnology Association (IowaBIO). The award recognizes an individual who demonstrates leadership in their organization and within the biotechnology industry. At IDx,
February 13, 2019
IDx-DR expands AI retinopathy exams for diabetes patients
IDx-DR, an artificial intelligence system that detects diabetic retinopathy, is expanding to new healthcare settings since the FDA first cleared the AI system to go to market in April 2018, startup IDx of Coralville reports. IDx-DR is now in use in clinics focusing on endocrinology, internal medicine, diabetes education, community health, diagnostics labs and diabetes research groups. In October, the company announced a new agreement with ophthalmic device manufacturer TopCon
October 25, 2018
IDx, Topcon sign exclusive AI platform agreement
Coralville company IDx, the first FDA-cleared autonomous AI diagnostic system, announced a new agreement with ophthalmic device manufacturer TopCon to scale delivery of the IDx diagnostics system for market, reports the Corridor Business Journal. The agreement grants exclusive rights to IDx in the U.S. as the only autonomous AI company permitted to sell products with the Topcon NW400, a robotic fundus camera. In turn, IDx agreed to assign the Topcon
July 26, 2018
Artificial intelligence begins diagnosing patients in eastern Iowa
The University of Iowa Hospitals and Clinics will be the first in the state to employ a Coralville company’s artificial intelligence diagnostics when scanning for diabetic retinopathy, the Cedar Rapids Gazette reports. The device, called IDx-DR and developed by IDx, received approval from the U.S. Food and Drug Administration in April. The technology takes images of a patient’s retina and analyzes the images to determine whether the retina has abnormalities
April 17, 2018
FDA approves first AI product for Coralville-based IDx
IDx, a University of Iowa spinout company based in Coralville, has received FDA approval to market IDx-DR, the first medical device to use artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy in adults who have diabetes. IDx recently announced a move to larger quarters in the Oakdale Research Park in Coralville and plans to expand staff as it commercializes IDx-DR, reports the Corridor
